Rafferty Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Rafferty Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.02M	Sell	37,676 -5,423	-13%	-$182K	﹤0.01%	766
2025 Q4	$1.85M	Buy	43,099 +29,421	+215%	+$1.11M	0.01%	663
2025 Q3	$387K	Sell	13,678 -4,620	-25%	-$138K	﹤0.01%	941
2025 Q2	$343K	Sell	18,298 -3,099	-14%	-$58.8K	﹤0.01%	956
2025 Q1	$385K	Buy	+21,397	New	+$434K	﹤0.01%	916
2022 Q3	–	Sell	-108,854	Closed	-$1.23M	–	1230
2022 Q2	$1.23M	Buy	108,854 +74,031	+213%	+$1.49M	0.01%	584
2022 Q1	$1.04M	Sell	34,823 -13,806	-28%	-$374K	0.01%	772
2021 Q4	$1.29M	Buy	48,629 +19,079	+65%	+$576K	0.01%	785
2021 Q3	$1.07M	Sell	29,550 -11,658	-28%	-$459K	0.01%	795
2021 Q2	$1.79M	Sell	41,208 -21,335	-34%	-$805K	0.01%	719
2021 Q1	$2.14M	Buy	62,543 +53,637	+602%	+$2.12M	0.01%	603
2020 Q4	$312K	Sell	8,906 -18,167	-67%	-$526K	﹤0.01%	799
2020 Q3	$650K	Buy	+27,073	New	+$665K	0.01%	647
2019 Q3	–	Sell	-28,317	Closed	-$739K	–	838
2019 Q2	$739K	Sell	28,317 -6,853	-19%	-$155K	0.01%	617
2019 Q1	$904K	Buy	+35,170	New	+$804K	0.01%	571

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's RIGL Position: Q1 2026 in Review

Rafferty Asset Management reduced its Rigel Pharmaceuticals (RIGL) stake by 13% in Q1 2026, selling an estimated $182K and leaving 37,676 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Rafferty Asset Management first reported a position in RIGL in Q1 2019 and has held it in 15 quarters since. The position peaked at $2.14M in Q1 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

Rafferty Asset Management held 37,676 shares of Rigel Pharmaceuticals worth $1.02M as of Q1 2026.
Rafferty Asset Management sold 5,423 Rigel Pharmaceuticals shares in Q1 2026, an estimated $182K.
Rigel Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #766 holding.
Rafferty Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2019 and has held it in 15 quarters since.
Rafferty Asset Management's Rigel Pharmaceuticals position peaked at $2.14M in Q1 2021.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.